Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)

NCT04412668 is registered in ClinicalTrials.gov with aTyr Pharma, Inc. as lead sponsor.

NCT NCT04412668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
Lead sponsor
aTyr Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2020
Completion date
October 23, 2020
Enrollment
36 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 (covid-19) severe pneumonia